Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BCC Research | PRODUCT CODE: 1532346

Cover Image

PUBLISHER: BCC Research | PRODUCT CODE: 1532346

Global Automated and Closed Cell Therapy Market

PUBLISHED:
PAGES: 112 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5500
PDF (2-5 Users)
USD 6600
PDF (Site License)
USD 7920
PDF (Enterprise License)
USD 9504

Add to Cart

The global market for automated and closed cell therapy is expected to grow from $1.8 billion in 2024 and is projected to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.9% during the forecast period of 2024 to 2029.

The North American market for automated and closed cell therapy is expected to grow from $752.2 million in 2024 and is projected to reach $2.1 billion by the end of 2029, at a CAGR of 22.3% during the forecast period of 2024 to 2029.

The European market for automated and closed cell therapy is expected to grow from $539.1 million in 2024 and is projected to reach $1.5 billion by the end of 2029, at a CAGR of 22.9% during the forecast period of 2024 to 2029.

Report Scope:

The report highlights the current and future market potential of automated and closed cell therapy systems and a detailed analysis of the market drivers, restraints, and opportunities. The report also covers market projections for 2029, a competitive environment, patent, and product analysis. The report provides market estimates and forecasts for automated and closed cell therapy based on automation, cell type, application, and region. The market is segmented into CAR-T cells, stem cells, and other cell types based on cell type. The market is categorized as clinical and commercial based on the application type. The market is segmented into semi-automated and fully automated based on the type of automation. The semi-automated systems are further segmented based on workflow into apheresis, expansion, fill-finish, separation, and others. The report includes company profiles of the key industry players with detailed information about their business segments, financials, product portfolios, and recent developments. The report does not cover automated systems for basic operations such as pipetting or mixing.

By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America-the U.S., Canada, and Mexico; Europe-Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific-China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecast through 2029.

Report Includes:

  • 43 data tables and 46 additional tables
  • An overview of the current and future global markets for automated and closed cell therapy
  • Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024 and projected CAGRs through 2029
  • Estimates of the market size and revenue forecasts, with market share analysis based on the automation type, cell type, application, and region
  • Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
  • Overview of the sustainability and ESG trends, with emphasis on the ESG practices followed by leading companies, their ESG rankings and consumer attitudes
  • Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding.
  • Profiles of the leading companies, including Danaher Corp., Thermo Fischer Scientific Inc., Lonza, and Sartorius AG
Product Code: BIO258A

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Insights

Chapter 2 Market Overview

  • Overview
  • Types of Cell Therapy
  • Applications of Cell Therapy
  • Regenerative Medicine
  • Cancer
  • Autoimmune Disorders

Chapter 3 Market Dynamics

  • Market Dynamics Snapshot
  • Market Drivers
  • Point-of-Care Manufacturing in CAR-T Therapies
  • Growing Demand for Regenerative Medicine
  • Market Restraints
  • High Costs and Integration Challenges
  • Regulatory Uncertainties
  • Market Opportunities
  • Increasing Startups in Cell Therapy Manufacturing
  • Scalable Platforms

Chapter 4 Emerging Technologies and Developments

  • Introduction
  • Real-Time Monitoring (RTM) of Operations
  • Off-the-Shelf Cell Therapies
  • Miniaturization of Cell Therapy Systems

Chapter 5 Market Segmentation Analysis

  • Segmentation Breakdown
  • Global Automated and Closed Cell Therapy Market by Automation Type
  • Semi-Automated Cell Therapy
  • Fully Automated Cell Therapy
  • Global Automated and Closed Cell Therapy Market by Cell Type
  • CAR-T Cells
  • Stem Cells
  • Other Cell Types
  • Global Automated and Closed Cell Therapy Market by Application
  • Market Size and Forecast
  • Clinical
  • Commercial
  • Geographic Breakdown
  • Global Market for Automated and Closed Cell Therapy by Region
  • Market Size and Forecast
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Chapter 6 Competitive Intelligence

  • Competitive Landscape
  • Partnerships
  • Investments and Funding
  • Patent Analysis

Chapter 7 Sustainability in the Automated and Closed Cell Therapy Market

  • Introduction
  • Sustainability in the Automated and Closed Cell Therapy Industry
  • Understanding the ESG Data
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Concluding Remarks from BCC

Chapter 8 Appendix

  • Methodology
  • Sources
  • Acronyms
  • Company Profiles
  • ADVA BIOTECHNOLOGY
  • BIOSPHERIX LTD.
  • CELLARES
  • DANAHER CORP.
  • FRESENIUS SE & CO. KGAA
  • LONZA
  • MILTENYI BIOTEC
  • SARTORIUS AG
  • TERUMO CORP.
  • THERMO FISHER SCIENTIFIC INC.
Product Code: BIO258A

List of Tables

  • Summary Table : Global Market for Automated and Closed Cell Therapy, by Region, Through 2029
  • Table 1 : Classification of Stem Cells
  • Table 2 : Comparison Between Autologous and Allogeneic Therapeutics
  • Table 3 : Companies with Off-the-Shelf Therapeutics Pipeline
  • Table 4 : Differences between Semi-Automation and Full Automation in Cell Therapy
  • Table 5 : Global Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
  • Table 6 : Select Semi-Automated Cell Therapy Systems
  • Table 7 : Global Market for Semi-Automated Cell Therapy, by Region, Through 2029
  • Table 8 : Global Market for Semi-Automated Cell Therapy, by Workflow, Through 2029
  • Table 9 : Global Market for Automated and Closed Apheresis, by Region, Through 2029
  • Table 10 : Global Market for Automated and Closed Expansion, by Region, Through 2029
  • Table 11 : Global Market for Automated and Closed Fill-Finish, by Region, Through 2029
  • Table 12 : Global Market for Automated and Closed Separation, by Region, Through 2029
  • Table 13 : Global Market for Other Automated and Closed Workflows, by Region, Through 2029
  • Table 14 : Global Market for Fully Automated Cell Therapy, by Region, Through 2029
  • Table 15 : Global Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
  • Table 16 : FDA-Approved CAR-T Cell Therapies
  • Table 17 : Global Market for Automated and Closed CAR-T Cell Therapy, by Region, Through 2029
  • Table 18 : Global Market for Automated and Closed Stem Cell Therapy, by Region, Through 2029
  • Table 19 : Global Market for Automated and Closed Other Cell Therapies, by Region, Through 2029
  • Table 20 : Global Market for Automated and Closed Cell Therapy, by Application, Through 2029
  • Table 21 : Global Market for Clinical Automated and Closed Cell Therapy, by Region, Through 2029
  • Table 22 : Global Market for Commercial Automated and Closed Cell Therapy, by Region, Through 2029
  • Table 23 : Global Market for Automated and Closed Cell Therapy, by Region, Through 2029
  • Table 24 : North American Market for Automated and Closed Cell Therapy, by Country, Through 2029
  • Table 25 : North American Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
  • Table 26 : North American Market for Semi-automated Automated and Closed Cell Therapy, by Workflow, Through 2029
  • Table 27 : North American Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
  • Table 28 : North American Market for Automated and Closed Cell Therapy, by Application, Through 2029
  • Table 29 : European Market for Automated and Closed Cell Therapy, by Country, Through 2029
  • Table 30 : European Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
  • Table 31 : European Market for Semi-Automated Automated and Closed Cell Therapy, by Workflow, Through 2029
  • Table 32 : European Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
  • Table 33 : European Market for Automated and Closed Cell Therapy, by Application, Through 2029
  • Table 34 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Country, Through 2029
  • Table 35 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
  • Table 36 : Asia-Pacific Market for Semi-Automated and Closed Cell Therapy, by Workflow, Through 2029
  • Table 37 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
  • Table 38 : Asia-Pacific Market for Automated and Closed Cell Therapy, by Application, Through 2029
  • Table 39 : RoW Market for Automated and Closed Cell Therapy, by Automation Type, Through 2029
  • Table 40 : RoW Market for Semi-Automated and Closed Cell Therapy, by Workflow, Through 2029
  • Table 41 : RoW Market for Automated and Closed Cell Therapy, by Cell Type, Through 2029
  • Table 42 : RoW Market for Automated and Closed Cell Therapy, by Application, Through 2029
  • Table 43 : Top Automated and Closed Cell Therapy Companies, 2023
  • Table 44 : Select Strategic Alliances in the Automated and Closed Cell Therapy Industry, 2022-2024
  • Table 45 : Major Funding Activities in the Automated and Closed Cell Therapy Industry, 2022-2024
  • Table 46 : Active Patents of the Key Competitor Companies, 2022-2024
  • Table 47 : ESG Rankings for Major Automated and Closed Cell Therapy, 2024*
  • Table 48 : ESG: Environmental Overview
  • Table 49 : ESG: Social Overview
  • Table 50 : ESG: Governance Overview
  • Table 51 : Report Sources
  • Table 52 : Glossary of Terms Used in the Automated and Closed Cell Therapy Market
  • Table 53 : Adva Biotechnology: Company Snapshot
  • Table 54 : Adva Biotechnology: Product Portfolio
  • Table 55 : Adva Biotechnology: News/Key Developments, 2024
  • Table 56 : Biospherix Ltd.: Company Snapshot
  • Table 57 : Biospherix Ltd.: Product Portfolio
  • Table 58 : Biospherix Ltd.: News/Key Developments, 2022
  • Table 59 : Cellares: Company Snapshot
  • Table 60 : Cellares: Product Portfolio
  • Table 61 : Cellares: News/Key Developments, 2024
  • Table 62 : Danaher Corp.: Company Snapshot
  • Table 63 : Danaher Corp.: Financial Performance, FY 2022 and 2023
  • Table 64 : Danaher Corp.: Product Portfolio
  • Table 65 : Danaher Corp.: News/Key Developments, 2024
  • Table 66 : Fresenius SE & Co. KGAA: Company Snapshot
  • Table 67 : Fresenius SE & Co. KGAA: Financial Performance, FY 2022 and 2023
  • Table 68 : Fresenius SE & Co. KGaA: Product Portfolio
  • Table 69 : Fresenius SE & Co. KGAA: News/Key Developments, 2023
  • Table 70 : Lonza: Company Snapshot
  • Table 71 : Lonza: Financial Performance, FY 2022 and 2023
  • Table 72 : Lonza: Product Portfolio
  • Table 73 : Lonza: News/Key Developments, 2022
  • Table 74 : Miltenyi Biotec: Company Snapshot
  • Table 75 : Miltenyi Biotec: Product Portfolio
  • Table 76 : Miltenyi Biotec: News/Key Developments, 2024
  • Table 77 : Sartorius AG: Company Snapshot
  • Table 78 : Sartorius AG: Financial Performance, FY 2022 and 2023
  • Table 79 : Sartorius AG: Product Portfolio
  • Table 80 : Sartorius AG: News/Key Developments, 2024
  • Table 81 : Terumo Corp.: Company Snapshot
  • Table 82 : Terumo Corp.: Financial Performance, FY 2022 and 2023
  • Table 83 : Terumo Corp.: Product Portfolio
  • Table 84 : Terumo Corp.: News/Key Developments, 2024
  • Table 85 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 86 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
  • Table 87 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 88 : Thermo Fisher Scientific Inc.: News/Key Developments, 2024

List of Figures

  • Summary Figure : Global Market Shares of Automated and Closed Cell Therapy, by Region, 2023
  • Figure 1 : Types of Cells Used in Cell Therapies
  • Figure 2 : Benefits of Automated and Closed Cell Therapy Manufacturing
  • Figure 3 : Market Dynamics of Global Automated and Closed Cell Therapy Market
  • Figure 4 : Workflow Involved in the Production of CAR-T Therapies
  • Figure 5 : Emerging Technologies in the Automated and Closed Cell Therapy Market
  • Figure 6 : Global Market Shares of Automated and Closed Cell Therapy, by Automation Type, 2023
  • Figure 7 : Global Market for Semi-Automated Cell Therapy, by Region, 2021-2029
  • Figure 8 : Global Market for Fully Automated Cell Therapy, by Region, 2021-2029
  • Figure 9 : Global Market Shares of Automated and Closed Cell Therapy, by Cell Type, 2023
  • Figure 10 : Global Market for Automated and Closed CAR-T Cell Therapy, 2021-2029
  • Figure 11 : Global Market for Automated and Closed CAR-T Cell Therapy, by Region, 2021-2029
  • Figure 12 : Global Market for Automated and Closed Stem Cell Therapy, 2021-2029
  • Figure 13 : Global Market for Automated and Closed Stem Cell Therapy, by Region, 2021-2029
  • Figure 14 : Global Market for Automated and Closed Other Cell Therapies, 2021-2029
  • Figure 15 : Global Market for Automated and Closed Other Cell Therapies, by Region, 2021-2029
  • Figure 16 : Global Market Shares of Automated and Closed Cell Therapy, by Application, 2023
  • Figure 17 : Global Market for Clinical Automated and Closed Cell Therapy, 2021-2029
  • Figure 18 : Global Market for Commercial Automated and Closed Cell Therapy, 2021-2029
  • Figure 19 : Global Market Shares of Automated and Closed Cell Therapy, by Region, 2023
  • Figure 20 : Global Market for Automated and Closed Cell Therapy, by Region, 2021-2029
  • Figure 21 : North American Market Shares of Automated and Closed Cell Therapy, by Country, 2023
  • Figure 22 : U.S. Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 23 : Canadian Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 24 : Mexican Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 25 : European Market Shares of Automated and Closed Cell Therapy, by Country, 2023
  • Figure 26 : German Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 27 : French Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 28 : Italian Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 29 : Spanish Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 30 : U.K. Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 31 : Rest of Europe Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 32 : Asia-Pacific Market Shares of Automated and Closed Cell Therapy, by Country, 2023
  • Figure 33 : Chinese Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 34 : Japanese Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 35 : Indian Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 36 : Australian Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 37 : South Korean Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 38 : Rest of Asia-Pacific Market for Automated and Closed Cell Therapy, 2021-2029
  • Figure 39 : Snapshot of the ESG Pillars
  • Figure 40 : Advantages of ESG for Companies
  • Figure 41 : ESG Goals of Automated and Closed Cell Therapy Companies
  • Figure 42 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
  • Figure 43 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
  • Figure 44 : Fresenius SE & Co. KGAA: Revenue Share, by Business Unit, FY 2023
  • Figure 45 : Fresenius SE & Co. KGAA: Revenue Share, by Country/Region, FY 2023
  • Figure 46 : Lonza: Revenue Share, by Business Unit, FY 2023
  • Figure 47 : Lonza: Revenue Share, by Country/Region, FY 2023
  • Figure 48 : Sartorius AG: Revenue Share, by Business Unit, FY 2023
  • Figure 49 : Sartorius AG: Revenue Share, by Country/Region, FY 2023
  • Figure 50 : Terumo Corp.: Revenue Share, by Business Unit, FY 2023
  • Figure 51 : Terumo Corp.: Revenue Share, by Country/Region, FY 2023
  • Figure 52 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
  • Figure 53 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!